Drug Profile
Anti-CD3-anti-MOv18 monoclonal antibody
Alternative Names: OC-TR; OC-TR bispecific monoclonal antibodyLatest Information Update: 26 Jul 2002
Price :
$50
*
At a glance
- Originator Centocor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 23 Jan 2001 Profile reviewed but no significant changes made
- 23 Jan 2001 Preclinical development for Ovarian cancer in Sweden (Intraperitoneal)
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline